8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
May 8, 2026·SEC
Material company update
Apr 16, 2026·SEC
Atossa Therapeutics, Inc.(ATOS)Earnings, Financials & Key Ratios
ATOS•NASDAQ
$1.88
Price updated Jun 27, 2026
AboutAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$37M-34.5%
- Net Income-$35M-36.3%
- EPS (Diluted)-4.04-34.7%
- ROE-62.74%-99.9%
ATOS Price & Volume
Atossa Therapeutics, Inc. (ATOS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Persistent Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
"Atossa Therapeutics remains a high-risk, pre-commercial biotechnology entity entirely dependent on external capital to fund its oncology research pipeline. While the company maintains a cash position of $31.7 million as of 2026Q1, the absence of revenue and the escalation of quarterly R&D expenses to $4.8 million suggest a narrowing window for clinical success. Investors should monitor the firm's ability to reach definitive Phase II endpoints before the current liquidity buffer, which has seen total assets decline from $96.3 million in 2023Q4 to $37.9 million, is fully exhausted."
Verdict Logic
the company's reliance on cash reserves to fund operations, evidenced by a current ratio compression from 17.61 in 2023Q4 to 4.92 in 2026Q1, presents significant long-term solvency risks for equity holders.
ATOS Growth Metrics
Atossa Therapeutics, Inc. (ATOS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-42.88%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-40.2%
Return on Capital
10 Years-90.75%
5 Years-35.5%
3 Years-43.68%
Last Year-67.02%
ATOS Recent Earnings
Atossa Therapeutics, Inc. (ATOS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$1.11-12.1%
$0.99
Rev
—
—
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$1.19-4.6%
$1.14
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$1.05+0.0%
$1.05
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.07-16.7%
$0.06
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $1.11vs $0.99-12.1% | — |
| Q2 2026 | Mar 25, 2026 | $1.19vs $1.14-4.6% | — |
| Q4 2025 | Nov 12, 2025 | $1.05vs $1.05+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.07vs $0.06-16.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Atossa Therapeutics, Inc. (ATOS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.88 | $16.19M | -0.47 | — | — | -62.74% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — | |
| $21.31 | $1.88B | -6.48 | 627.84% | -112.01% | -256.66% | — | |
| $4.70 | $190.82M | 3.85 | 36.55% | -19.55% | -3.39% | — | |
| $31.00 | $3.12B | -9.42 | -4.26% | -156.36% | -68.97% | — | |
| $3.03 | $126.18M | -891.18 | 10.37% | 52.16% | — | — |
Compare ATOS vs Peers
Atossa Therapeutics, Inc. (ATOS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATOS SEC Filings & Documents
Atossa Therapeutics, Inc. (ATOS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ATOS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATOS Frequently Asked Questions
Atossa Therapeutics, Inc. (ATOS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ATOS profitable?
Atossa Therapeutics, Inc. (ATOS) reported a net loss of $37.6M for fiscal year 2025.
Dividend & Returns
What is ATOS's return on equity?
Atossa Therapeutics, Inc. (ATOS) has a return on equity (ROE) of -62.7%. Negative ROE indicates the company is unprofitable.
What is Atossa Therapeutics, Inc.'s free cash flow?
Atossa Therapeutics, Inc. (ATOS) had negative free cash flow of $33.4M in fiscal year 2025, likely due to heavy capital investments.